Citigroup’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Citigroup’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,900	Closed	-$1.27M	–	5898
2023 Q4	$1.27M	Buy	+29,900	New	+$859K	﹤0.01%	2630
2023 Q2	–	Sell	-30,000	Closed	-$732K	–	5780
2023 Q1	$732K	Buy	30,000 +6,600	+28%	+$194K	﹤0.01%	2817
2022 Q4	$738K	Buy	+23,400	New	+$660K	﹤0.01%	2887

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Citigroup's CERE Position: Q3 2024 in Review

Citigroup sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,284,070 shares — an estimated $52.5M sold.

Citigroup first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $80.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Citigroup reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Citigroup sold 1,284,070 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $52.5M.
Citigroup first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
Citigroup's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $80.1M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Citigroup's 13F filing for Q3 2024, filed 12 Nov 2024.